Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$43.2MCash, Jun 2026
19moCash Runway (est.)
+40%Share Count, 1 Year
Follow COYA by emailGet an email when COYA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about COYA, unsubscribe in one click. Privacy
📣 What COYA Says Is Next
coming months · “At the same time, we plan to initiate a Phase 2 study of COYA 302 in frontotemporal dementia (FTD) in the coming months.”
Company press release, Aug 11, 2026 · SEC filing
this year · ““Enrollment in the ALSTARS Phase 2 ALS trial is proceeding as planned, and we remain on track to complete enrollment this year and report topline data in the first quarter of 2027.”
Company press release, Aug 11, 2026 · SEC filing
1Q 2027 · ““The ALSTARS trial is now in full recruitment mode, and we maintain our guidance for a 1Q 2027 topline readout.”
Company press release, May 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
COYA reported $43.2M in cash and short-term investments (as of Jun 30, 2026) and used about $6.8M/quarter in operations, an estimated runway of 18.9 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for COYA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.